Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of SARS-CoV-2 vaccines in patients with rheumatic diseases
2021-002245-15Phase 4Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Apr 2021
- Countries
- 1
01
Overview
Phase 4, open-label trial of SARS-CoV-2 vaccine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Humoral and/or cellular vaccination response after SARS-CoV-2 vaccination. Started Apr 2021; status: completed.
02
Drugs
SARS-CoV-2 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-002245-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002245-15.